Hydrazide Contrast Agents for Necrotic Tissue Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current contrast agents for medical imaging, particularly those used in MRI, face challenges such as instability, toxicity, slow clearance rates, and difficulty in targeting specific tissues, leading to overlapping imaging signals between pathological and normal tissues, which complicates unambiguous diagnosis.
Innovation Solution
Development of contrast agents featuring a hydrazide functional group that targets necrotic tissue, comprising a metal ion bound to a metal-complexable portion and a linker joining the targeting and metal-complexable portions, allowing for enhanced localization and visualization of necrotic tissue.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If porphyrin-based contrast agents are used to achieve targeting capabilities, then tissue targeting ability is improved, but stability and clearance rate worsen
Solution Approach 1:
The patent changes the chemical structure parameters by replacing porphyrin cores with non-porphyrin alternatives (such as BODIPY, cyanine, and other fluorophores) while adjusting molecular weight, hydrophobicity, and functional group composition to achieve both targeting capability and improved stability-clearance profile
Solution Approach 2:
The contrast agents are designed as composite structures combining a fluorophore core, targeting ligand (such as RGD peptide, transferrin, or antibody fragments), and optionally a contrast agent moiety (gadolinium chelate, iodine-containing group, or radioactive isotope), allowing simultaneous achievement of targeting, stability, and clearance optimization
2Measurement precision
If contrast agents are used to improve visualization of internal structures, then imaging capability is improved, but overlap in imaging signals between pathological and normal tissues persists
Solution Approach 1:
The contrast agents are designed with specific targeting ligands that bind to receptors or structures uniquely present or overexpressed in pathological tissues (such as integrins in tumor vasculature, transferrin receptors in cancer cells, or enzymes in necrotic tissue), creating localized high-concentration accumulation that produces distinct imaging signals only at the disease site while normal tissues remain unaffected
Solution Approach 2:
The patent optimizes kinetic parameters including blood pool residence time, tissue penetration rate, and cellular uptake efficiency by adjusting molecular size, charge, and hydrophobicity, thereby achieving temporal and spatial separation of contrast agent distribution between normal and pathological tissues that enables unambiguous diagnostic imaging
3Illumination intensity
If conventional contrast agents are administered to highlight specific areas, then visibility of studied areas is improved, but adverse effects increase
Solution Approach 1:
The patent extracts and separates the imaging function from the toxic components by using biocompatible fluorophores that emit light or alter magnetic properties without the systemic toxicity of iodine-based CT contrast agents or gadolinium deposition issues, thereby maintaining visibility improvement while eliminating harmful effects
Solution Approach 2:
The contrast agents are designed with molecular structures that enable rapid renal clearance or hepatobiliary elimination within hours of administration, preventing accumulation and long-term toxicity, effectively making them short-lived agents that complete their diagnostic function before being eliminated without causing persistent adverse effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These contrast agents effectively localize to necrotic tissue, improving diagnostic accuracy by providing clear differentiation between necrotic and normal tissues, with prolonged retention in necrotic tissue areas, enabling better monitoring of tissue health and therapeutic effectiveness.
Implementation Method 1
Contrast agents for MRI technology alter the relaxation times of tissues and body cavities where they are located and work by shortening the relaxation time of protons located nearby
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Described herein is a contrast agent for administration to a subject. The contrast agent includes a targeting portion that includes a hydrazide functional group; a metal ion bound to a metal-complexable portion; and a linker joining the targeting portion and the metal- complexable portion of the contrast agent. The portion that is not bound to a metal ion localizes the contrast agent to necrotic tissue in the subject.